A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment
/in Dendritic Cells, International Publications, Prostate CancerImmune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine
/in Dendritic Cells, Esophageal Carcinoma, International PublicationsClinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
/in Acute Leukemia, Chronic Leukemia, Dendritic Cells, International Publications, Malignant LymphomaImmunotherapy for castration-resistant prostate cancer: Progress and new paradigms
/in Dendritic Cells, International Publications, Prostate CancerPotential approaches for more successful dendritic cell-based immunotherapy
/in Dendritic Cells, International PublicationsPrognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic CancerImmunotherapy of hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer